Maximizing the impact of the Cures Acceleration Network: accelerating the development of new drugs and diagnostics : workshop summary
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into c...
Gespeichert in:
| Körperschaft: | |
|---|---|
| Weitere beteiligte Personen: | , |
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Washington, District of Columbia
National Academies Press
[2012]
|
| Schlagwörter: | |
| Zusammenfassung: | Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description |
| Beschreibung: | Description based on print version record |
| Umfang: | 1 online resource (131 pages) |
| ISBN: | 9780309261166 0309261163 9780309261173 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044056040 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2012 xx o|||| 00||| eng d | ||
| 020 | |a 9780309261166 |c Print |9 978-0-309-26116-6 | ||
| 020 | |a 0309261163 |c Print |9 0-309-26116-3 | ||
| 020 | |a 9780309261173 |c ebook |9 978-0-309-26117-3 | ||
| 035 | |a (ZDB-30-PAD)EBC3379066 | ||
| 035 | |a (ZDB-89-EBL)EBL3379066 | ||
| 035 | |a (ZDB-38-EBR)ebr10863714 | ||
| 035 | |a (OCoLC)829421146 | ||
| 035 | |a (DE-599)BVBBV044056040 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615.1/9 |2 23 | |
| 110 | 2 | |a Institute of Medicine (U.S.) |b Forum on Drug Discovery, Development, and Translation |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Maximizing the impact of the Cures Acceleration Network |b accelerating the development of new drugs and diagnostics : workshop summary |c Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| 246 | 1 | 3 | |a Accelerating the development of new drugs and diagnostics |
| 264 | 1 | |a Washington, District of Columbia |b National Academies Press |c [2012] | |
| 264 | 4 | |c © 2012 | |
| 300 | |a 1 online resource (131 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on print version record | ||
| 520 | |a Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description | ||
| 610 | 2 | 4 | |a United States |b Institutes of Health |b National Center for Advancing Translational Sciences |b Cures Acceleration Network |
| 650 | 4 | |a Drug monitoring | |
| 650 | 4 | |a Drug development |z United States | |
| 650 | 4 | |a Drugs |z United States |x Design | |
| 650 | 4 | |a Pharmaceutical industry |z United States |x Quality control | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Olson, Steve |d 1956- |4 ctb | |
| 700 | 1 | |a Claiborne, Anne B. |4 ctb | |
| 710 | 2 | |a National Institute of Medicine (U.S.)XXbBoard on Health Sciences PolicyXXeissuing body |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Institute of Medicine (U.S.). Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary |
| 912 | |a ZDB-30-PAD | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-029462885 | |
Datensatz im Suchindex
| _version_ | 1818982772618821632 |
|---|---|
| any_adam_object | |
| author2 | Olson, Steve 1956- Claiborne, Anne B. |
| author2_role | ctb ctb |
| author2_variant | s o so a b c ab abc |
| author_corporate | Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation |
| author_corporate_role | aut |
| author_facet | Olson, Steve 1956- Claiborne, Anne B. Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation |
| author_sort | Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation |
| building | Verbundindex |
| bvnumber | BV044056040 |
| collection | ZDB-30-PAD |
| ctrlnum | (ZDB-30-PAD)EBC3379066 (ZDB-89-EBL)EBL3379066 (ZDB-38-EBR)ebr10863714 (OCoLC)829421146 (DE-599)BVBBV044056040 |
| dewey-full | 615.1/9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1/9 |
| dewey-search | 615.1/9 |
| dewey-sort | 3615.1 19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03744nam a2200493zc 4500</leader><controlfield tag="001">BV044056040</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2012 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309261166</subfield><subfield code="c">Print</subfield><subfield code="9">978-0-309-26116-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309261163</subfield><subfield code="c">Print</subfield><subfield code="9">0-309-26116-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309261173</subfield><subfield code="c">ebook</subfield><subfield code="9">978-0-309-26117-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC3379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL3379066</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-38-EBR)ebr10863714</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)829421146</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044056040</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1/9</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Maximizing the impact of the Cures Acceleration Network</subfield><subfield code="b">accelerating the development of new drugs and diagnostics : workshop summary</subfield><subfield code="c">Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Accelerating the development of new drugs and diagnostics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, District of Columbia</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">[2012]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (131 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on print version record</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States</subfield><subfield code="b">Institutes of Health</subfield><subfield code="b">National Center for Advancing Translational Sciences</subfield><subfield code="b">Cures Acceleration Network</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield><subfield code="x">Quality control</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve</subfield><subfield code="d">1956-</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Claiborne, Anne B.</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">National Institute of Medicine (U.S.)XXbBoard on Health Sciences PolicyXXeissuing body</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Institute of Medicine (U.S.). Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029462885</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV044056040 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T17:52:32Z |
| institution | BVB |
| isbn | 9780309261166 0309261163 9780309261173 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029462885 |
| oclc_num | 829421146 |
| open_access_boolean | |
| physical | 1 online resource (131 pages) |
| psigel | ZDB-30-PAD |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation Verfasser aut Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies Accelerating the development of new drugs and diagnostics Washington, District of Columbia National Academies Press [2012] © 2012 1 online resource (131 pages) txt rdacontent c rdamedia cr rdacarrier Description based on print version record Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description United States Institutes of Health National Center for Advancing Translational Sciences Cures Acceleration Network Drug monitoring Drug development United States Drugs United States Design Pharmaceutical industry United States Quality control USA Olson, Steve 1956- ctb Claiborne, Anne B. ctb National Institute of Medicine (U.S.)XXbBoard on Health Sciences PolicyXXeissuing body Sonstige oth Erscheint auch als Druck-Ausgabe Institute of Medicine (U.S.). Maximizing the impact of the Cures Acceleration Network : accelerating the development of new drugs and diagnostics : workshop summary |
| spellingShingle | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary United States Institutes of Health National Center for Advancing Translational Sciences Cures Acceleration Network Drug monitoring Drug development United States Drugs United States Design Pharmaceutical industry United States Quality control |
| title | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary |
| title_alt | Accelerating the development of new drugs and diagnostics |
| title_auth | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary |
| title_exact_search | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary |
| title_full | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Maximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Maximizing the impact of the Cures Acceleration Network |
| title_sort | maximizing the impact of the cures acceleration network accelerating the development of new drugs and diagnostics workshop summary |
| title_sub | accelerating the development of new drugs and diagnostics : workshop summary |
| topic | United States Institutes of Health National Center for Advancing Translational Sciences Cures Acceleration Network Drug monitoring Drug development United States Drugs United States Design Pharmaceutical industry United States Quality control |
| topic_facet | United States Institutes of Health National Center for Advancing Translational Sciences Cures Acceleration Network Drug monitoring Drug development United States Drugs United States Design Pharmaceutical industry United States Quality control USA |
| work_keys_str_mv | AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT olsonsteve maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT claiborneanneb maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT nationalinstituteofmedicineusxxbboardonhealthsciencespolicyxxeissuingbody maximizingtheimpactofthecuresaccelerationnetworkacceleratingthedevelopmentofnewdrugsanddiagnosticsworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation acceleratingthedevelopmentofnewdrugsanddiagnostics AT olsonsteve acceleratingthedevelopmentofnewdrugsanddiagnostics AT claiborneanneb acceleratingthedevelopmentofnewdrugsanddiagnostics AT nationalinstituteofmedicineusxxbboardonhealthsciencespolicyxxeissuingbody acceleratingthedevelopmentofnewdrugsanddiagnostics |